deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT01025193

Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant

One Year Exploratory Study to Evaluate the Efficacy and Safety of Belimumab for Normalization of Alloantibody Levels in Sensitized Patients Awaiting Kidney Transplantation

Sponsor: Human Genome Sciences Inc.

Conditions Desensitization
Interventions Belimumab
Updated 9 times since 2017 Last updated: May 9, 2017 Started: Feb 28, 2010 Primary completion: Oct 31, 2011 Completion: Nov 30, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

has not demonstrated efficacy in primary goal

Other terminated trials from Human Genome Sciences Inc.

More terminations from Human Genome Sciences Inc.

This PHASE2 trial investigates Desensitization and is currently terminated or withdrawn. Human Genome Sciences Inc. leads this study, which shows 9 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~May 2017 · 3 months · monthly snapshotTerminated~May 2017 – ~Jul 2017 · 2 months · monthly snapshotTerminated~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 4 earlier versions

  1. Jul 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  2. May 2017 — Jul 2017 [monthly]

    Terminated PHASE2

  3. Feb 2017 — May 2017 [monthly]

    Terminated PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Human Genome Sciences Inc.
  • University of Pennsylvania
Data source: University of Pennsylvania

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations